Core Insights - Shares of Swiss biotech MoonLake Immunotherapeutics fell 88% to $7.45 in premarket trading following the release of mixed results from two late-stage trials of its experimental skin drug [1] Company Summary - MoonLake Immunotherapeutics reported mixed outcomes from two late-stage trials, which significantly impacted its stock price [1] - The drastic decline in share price indicates a strong negative market reaction to the trial results [1] Industry Context - The biotech industry is often sensitive to clinical trial outcomes, with significant stock price volatility observed in response to trial results [1]